Generation Bio Soars 27.65% on ctLNP Breakthrough

On August 13, 2025, Generation Bio's stock surged by 27.65% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Generation Bio recently announced new data for its novel cell-targeted lipid nanoparticle (ctLNP) delivery system, highlighting its highly selective profile and the first-ever siRNA delivery to T cells in non-human primates. This breakthrough is a significant milestone for the company, demonstrating the potential of its technology in advancing therapeutic applications.

The company also reported an 81% drop in Q2 revenue, which has raised concerns among investors. However, updates on intellectual property, the status of the ctLNP technology, and any indications that the pipeline may advance to clinical trials will be crucial in determining the company's future prospects.

In a recent study, Generation Bio successfully delivered siRNA to T cells in primates, showing a 0.5 mg/kg dose of ctLNP-siRNA resulted in knockdown of beta-2 microglobulin in T cells over three weeks. This achievement underscores the company's progress in developing innovative therapeutic solutions.